We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Overview
- Systemic sclerosis (scleroderma)
- Overview of the pathogenesis of SSc
- Gene-environment interactions in SSc
- Genetic susceptibility & gene-environment interactions
- Established environmental risk factors
- Environmental factors
- Silica exposure
- Silica, implants, and SSc
- Organic solvents
- Heavy metals & other exposures
- Epigenetic mechanisms
- Epigenetic impact of toxins
- Infectious triggers
- Microbiome alterations in SSc
- Medications associated with SSc-like skin changes or SSc
- Summary
- Thank you
Topics Covered
- Systemic sclerosis (scleroderma)
- Pathogenesis of systemic sclerosis (SSc)
- Gene-susceptibility and gene-environment interaction in SSc
- Environmental risk factors
- Epigenetic impact of toxins
- Infectious triggers
- Microbiome alteration in SSc
- Medications associated with scleroderma-like skin changes or scleroderma
Links
Categories:
Therapeutic Areas:
Talk Citation
McMahan, Z. (2026, October 29). The environment & scleroderma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 29, 2026, from https://doi.org/10.69645/LZIG8817.Export Citation (RIS)
Publication History
- Published on October 29, 2026
Financial Disclosures
- Disclosure: Boehringer Ingelheim, Abbvie, Prolium Biosciences, Allogene Therapeutics, Aera Therapeutics.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone, and thank
you for joining me today.
My name is Dr.
Zsuzsanna McMahan,
and I'm an Associate
Professor of Medicine
and Co-Director of the
Scleroderma Center
at UTHealth Houston.
Today, we are going
to talk about a topic
that I'm frequently asked
about in the clinic,
the relationship between the
environment and scleroderma.
We'll explore how the
world around us interacts
with our biology to
influence this disease.
0:27
Before we begin, I wanted to
share my disclosures,
which are listed here.
0:34
Here is a brief roadmap of
what we will cover today.
First, we will look
at the big picture.
What exactly is the
relationship between
the environment and systemic
sclerosis or scleroderma?
Second, we'll break down
the core mechanisms.
Meaning, how exactly do
outside factors cause
changes inside the body?
Finally, we will
discuss how genetics,
the environment, and
something called epigenetics
all integrate and work together
to trigger or
worsen the disease.
1:03
To start, let's ground ourselves
in what systemic sclerosis is.
Systemic sclerosis, also
known as scleroderma,
is a rare autoimmune
disease affecting
roughly 250 out of every
one million people.
As many of you know firsthand,
it is characterized
by the hardening and
tightening of the skin
and connective tissues,
but it can also affect
internal organs.
Because it is so
rare and complex,
understanding exactly
why it happens
is one of our
biggest challenges,
and that is where the
environment comes into play.
1:37
This graphic gives
us an overview of
how scleroderma develops,
or its pathogenesis.
It essentially involves
three main events.
First, there's an injury
to the blood vessels.
Second, the immune system
becomes overactive
and starts attacking
the body's own tissues.
Third, this leads to fibrosis,
which is an overproduction
of collagen that causes
the tissue hardening that
we see in scleroderma.
The key question
for researchers is
what pulls the trigger to
start this three-step process?